

## **APPBP2 Antibody (Center)**

Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP16727c

### Specification

## **APPBP2 Antibody (Center) - Product Information**

Application Primary Accession Other Accession Reactivity Predicted Host Clonality Isotype Calculated MW Antigen Region WB,E <u>O92624</u> <u>A5HK05</u>, <u>O9DAX9</u>, <u>NP\_006371.2</u> Human Mouse, Rat Rabbit Polyclonal Rabbit IgG 66853 243-271

## **APPBP2** Antibody (Center) - Additional Information

Gene ID 10513

**Other Names** 

Amyloid protein-binding protein 2, Amyloid beta precursor protein-binding protein 2, APP-BP2, Protein interacting with APP tail 1, APPBP2, KIAA0228, PAT1

### Target/Specificity

This APPBP2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 243-271 amino acids from the Central region of human APPBP2.

Dilution WB~~1:1000

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

#### Precautions

APPBP2 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.

## **APPBP2** Antibody (Center) - Protein Information

Name APPBP2 {ECO:0000303|PubMed:26138980, ECO:0000312|HGNC:HGNC:622}



**Function** Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation (PubMed:<u>29779948</u>, PubMed:<u>29775578</u>). The C-degron recognized by the DesCEND pathway is usually a motif of less than ten residues and can be present in full-length proteins, truncated proteins or proteolytically cleaved forms (PubMed:<u>29779948</u>, PubMed:<u>29775578</u>). The CRL2(APPBP2) complex specifically recognizes proteins with a -Arg-Xaa- Xaa-Gly degron at the C-terminus, leading to their ubiquitination and degradation (PubMed:<u>29775578</u>). The CRL2(APPBP2) complex mediates ubiquitination and degradation of truncated SELENOV selenoproteins produced by failed UGA/Sec decoding, which end with a -Arg-Xaa-Xaa-Gly degron (PubMed:<u>26138980</u>). May play a role in intracellular protein transport: may be involved in the translocation of APP along microtubules toward the cell surface (PubMed:<u>9843960</u>).

### **Cellular Location**


Nucleus. Cytoplasm, cytoskeleton. Membrane; Peripheral membrane protein. Note=Associated with membranes and microtubules.

## **APPBP2 Antibody (Center) - Protocols**


Provided below are standard protocols that you may find useful for product applications.

- <u>Western Blot</u>
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- <u>Immunofluorescence</u>
- Immunoprecipitation
- Flow Cytomety
- <u>Cell Culture</u>

## **APPBP2 Antibody (Center) - Images**



Anti-APPBP2 Antibody (Center) at 1:1000 dilution + Jurkat whole cell lysate Lysates/proteins at 20  $\mu$ g per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 67 kDa Blocking/Dilution buffer: 5% NFDM/TBST.



APPBP2 Antibody (Center) (Cat. #AP16727c) western blot analysis in 293 cell line lysates (35ug/lane).This demonstrates the APPBP2 antibody detected the APPBP2 protein (arrow).

# APPBP2 Antibody (Center) - Background

The protein encoded by this gene interacts with microtubules and is functionally associated with beta-amyloid precursor protein transport and/or processing. The beta-amyloid precursor protein is a cell surface protein with signal-transducing properties, and it is thought to play a role in the pathogenesis of Alzheimer's disease. This gene has been found to be highly expressed in breast cancer. Multiple polyadenylation sites have been found for this gene.

## APPBP2 Antibody (Center) - References

Venkatesan, K., et al. Nat. Methods 6(1):83-90(2009) Benboudjema, L., et al. J. Virol. 77(17):9192-9203(2003) Gao, Y., et al. Proc. Natl. Acad. Sci. U.S.A. 98(26):14979-14984(2001) Monni, O., et al. Proc. Natl. Acad. Sci. U.S.A. 98(10):5711-5716(2001) Barlund, M., et al. Cancer Res. 60(19):5340-5344(2000)